← Back to patent-cliff list
LP-118
Tier C — Watch / tradeLP-118
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：BCL2, Bcl-X
Indications (approved)：Leukaemia, Acute lymphoblastic leukaemia, Lymphocytic leukaemia, T-细胞幼淋巴细胞白血病, Multiple myeloma, Non-Hodgkin lymphoma, Myelofibrosis, 骨髓增生异常-骨髓增生性疾病
Regional status
US
Phase II
2024-09-13
EU
-
China
Phase I
2021-09-08
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of LP-118?
Approved indications include: Leukaemia, Acute lymphoblastic leukaemia, Lymphocytic leukaemia, T-细胞幼淋巴细胞白血病, Multiple myeloma, Non-Hodgkin lymphoma, Myelofibrosis, 骨髓增生异常-骨髓增生性疾病.
When does the LP-118 patent expire?
No public expiry year is available for LP-118 yet; this page updates once verified.
How do I get a quote for LP-118 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01